Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.

You may also be interested in...



Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders

Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.

Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders

Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.

Pfizer Launches Phase III Trial For Sutent In Non-Small Cell Lung Cancer

Positive preliminary Phase II results on sunitinib/erlotinib combination therapy were presented at major lung cancer meeting this week in South Korea.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By